Good morning.
NVDA +7% premarket. Nasdaq futures ripping, European semis all green — the referendum passed. Demand debate closed: FY28 guide ~70% growth vs street at 44%, unconstrained demand ~100%. (Supply-constrained, not demand-constrained — that's the whole print.)
Memory inflation's second wave lands today: SEMCO lifts Q4 MLCC contract prices 25-30%, HP posts record revenue but PC unit declines. Pass-through tax hits the weakest pockets. Pricing power upstream, volume destruction downstream.
CRM beat and dropped Claudeforce — software goes from short-cover to narrative repricing. Labs need incumbents for distribution. The 3-day volume test starts tonight.
Asia: BOK hikes again to 3% (AI boom insurance), EM fear gauge falls at fastest pace in six years. YMTC files STAR IPO with a $5B single-quarter profit — Chinese NAND suddenly has both pricing power and capex ammo.
Three themes frame the day. First, NVDA supply commitments jump from $119B to $279B — memory is the binding constraint, margins trough at 71-72% in FQ4, recover after. That ~30pt gap between demand and guide IS the bull case in management's own words. Second, the financing layer formalizes: $279B commitments, $12.9B Hugging Face talk, Anthropic-Nscale $45B deal — a balance sheet war for compute. Third, Friday's Warsh Jackson Hole debut is the discount-rate gate on every crowded AI long — hedge books already leaning long USD into it.
We'll hit up NVDA, CRM, and MU first, then get to semis and software.
The crowd was wrong. Street had written off second-half reacceleration. Price targets clustered at $200-250. The stock paid for it — DOWN 22% YTD into the print. Then CRM dropped a quarter with a cRPO beat (FIRST IN THREE QUARTERS), a Q3 cRPO guide ABOVE the Street (+14% vs +13% est), and a CFO who told investors net new AOV growth hit a FOUR-YEAR HIGH. Stock ripped 13% after hours.
Now the hard part: one-quarter relief rally or the start of a re-rate? The answer hinges on whether AI attach (Agentforce ARR $1.5B, +240% YoY; D360+Agentforce combined $3.9B, +210%) translates into organic core reacceleration. Not just cRPO — revenue. The print validated the product story. It didn't yet validate the growth story.
Thirteen firms updated post-print. PT range: $195 (Bernstein, Underperform) to $315 (Citizens, Market Outperform). Median ~$265. The bull cluster sits at $260-300 — Jefferies at $300, Stifel/Baird/Oppenheimer all at $275, Guggenheim $270, Mizuho $265, BMO $260. Cantor holds $250 Overweight.
The interesting action is at the bottom. Even the skeptics raised targets — Wells Fargo to $230 (Equal Weight), DA Davidson to $200 (Neutral), Bernstein to $195 (Underperform). Nobody doubled down on the bear case. That's the tell. The consensus shifted from "growth is structurally dead" to "OK, fine, maybe they reaccelerate — but we're not paying up for it."
Bulls have the data this morning. cRPO +14% cc, first beat in three quarters, and management guided Q3 to +14% — a point above the Street bogey. Net new AOV at a FOUR-YEAR HIGH, Agentforce ARR accelerating from 205% to 240%, and the combined D360/Agentforce stack marches $2.9B → $3.4B → $3.9B across the last three quarters. At 13x CY27 FCF with a PEG of 0.6, the market's still pricing a permanently sub-10% grower. The AI product cycle breaks that logic.
Bears have a cleaner retort than the tape suggests. The core business hasn't reaccelerated. Q3 organic guide implies ~7% — flat against Q2 — and Informatica still carries >4pp of the reported growth. The EPS "beat" had a $2.53 strategic investment gain inside it: ex-gain, a $0.10 beat on a $42B revenue base. Beat magnitude narrowed for the THIRD straight quarter while Marketing, Commerce, and Tableau all drag. Blends to 7-8% no matter how fast Agentforce grows.
"The question remains whether Salesforce can accelerate organically or must acquire to drive better than 6% to 8% growth." > — Bernstein
New this quarter:
"Net new annual order value growth was the strongest in four years, keeping the company on track for second-half organic revenue reacceleration." > — CFO Robin Washington (via Guggenheim)
"Sales executives are returning from AI labs and highlighted upcoming innovation and customer announcements at Dreamforce." > — Jefferies
"Salesforce beat current remaining performance obligation in the quarter for the first time since the third quarter of 2026." > — BMO Capital
CRM just handed the legacy SaaS complex a playbook. The market had dumped the app layer into one "gets disrupted by AI agents" bucket — CRM down 22% YTD, Adobe stuck in the mud, Workday in the penalty box. CRM's counter: partner with the disruptor (Anthropic), bundle the agent product into the platform, and mine the installed base for expansion spend (50% of bookings). It's working.
Peers:
Post-print pop puts CRM at $205.62. Clears the last meaningful resistance, but it's no new ATH. The easy money was the +13% after-hours move. New money needs Q3 confirmation.
Catalysts: Baird's early-September management meeting (pre-Dreamforce), Dreamforce itself, and the November Q3 print. The evidence stack: cRPO guide +14% vs Street +13%, organic revenue ~7.1% per Wells Fargo, D360/Agentforce trajectory. If Q3 shows even 100bps of organic reaccel, the $260-300 targets come into play. If it prints in-line and management leans on Contentful/Fin for optics, Bernstein's "acquire your way to 8%" critique takes over the narrative.
R/R at $205: decent, not great. The print killed the strongest bear pillar — "CRM can't beat on cRPO." It didn't replace it with a clean organic acceleration story. That's a Q3 problem. Or an opportunity.
NVDA reset the framework. The buy-side came in expecting a beat-and-raise. What they got was a first-ever formal forward-year revenue guide that recalibrates the entire AI supply chain narrative. Growth guidance of ~70% for FY28 — versus the ~45% consensus bogey — is the whole story. Everything else is detail.
The PT range is wide — Argus at $270 (the "I still need to see it" price) to Melius at $420 (the "this is a $2T TAM winner" price). The meat of the Street sits between $315 and $350. The cluster: Stifel and Mizuho at $315, JPMorgan at $320, KeyBanc at $330, BofA and Cantor at $350. Bernstein stands out at $400. Rosenblatt at $390.
Goldman is the notable laggard — raised to $300 but STILL NEUTRAL. That's the tell: the stock is $5.08T, P/E of 32x, and the guide doesn't move the needle for GS. They see the bar already set at "most optimistic buyside expectations."
Mizuho's math shows the scale of the reset: FY28 revenue ~$700B vs $574B consensus. Cantor frames it as CY27 revenue of $685-690B — that's $127B ABOVE the $558B consensus. This isn't an increment. It's a step-change.
This quarter wasn't about the beat — it was about management changing the disclosure game.
Bull: Demand is 100%+ while supply grows at 70%. That gap is the bull case. Dollar content per gigawatt scales from ~$25B (Blackwell) to ~$40B (Rubin) to $50B+ over time. BofA raised FY28 EPS 19% to $15.72 and sees CY30 EPS above $31. The balance sheet lets NVDA buy the entire HBM supply chain out from under competitors. Melius says EPS above $20 in two years with 50%+ share of a $2T TAM before 2030.
"The Compute segment is sold out." — Cantor Fitzgerald
"The gross margin reset reflects a memory cost pass-through rather than pricing erosion. Price increases take effect in FQ1 FY28, and ~$350B of supply commitments convert cost exposure into volume firmness." — Stifel
Bear: The margin reset is real. 72-73% is a structural step-down from 75%. If memory costs keep inflating, the "bottom in FQ4" call looks optimistic. And there's the Goldman problem: the guide merely met the most optimistic buy-side expectations. The stock held gains, but at $5.08T, NVDA needs perfection. The quarter was a beat-and-raise. The guide was a beat-and-recalibrate. That's not the same as a beat-and-accelerate. The r/r at 32x earnings — even with a 0.29 PEG — is entirely dependent on flawless execution of a $500B financing platform that has no precedent.
This print is a macro signal for the whole AI complex. Supply chain tightness means memory names win — NVDA's $279B commitments are a pricing floor for HBM. COHR and the opticals complex are the next constraint — Coherent already flagged "extraordinary demand" with supply shortfalls for 12-18 months. AVGO and MRVL benefit from the same cap-ex supercycle, though the custom ASIC narrative still chases NVDA's coattails. The China angle — Goldman flagged MiniMax's 283% revenue growth — keeps the "AI is global" theme alive as US hyperscaler capex backstops the core.
The bigger read-through: NVDA is no longer just a semis story. The $500B private capital platform with the biggest names in alternatives makes NVDA a financial intermediary for AI infrastructure. That's a different kind of company than the one that was just selling GPUs. The trajectory of the stock matters less than the trajectory of the ecosystem. The ecosystem just got bigger.
OKTA IS THE AI IDENTITY STORY FINALLY PRINTING. cRPO +14% — a 300bps beat. New ACV +50%. Record non-Q4 bookings. And management STILL won't put agentic AI in guidance. Clean print today, free optionality tomorrow. Stock up ~85% over six months, another +21% after-hours. The tape has decided.
Ten firms moved post-print. PT range: $165 (Mizuho, Neutral) to $200 (Cantor, Overweight). The consensus cluster sits $175-190: Stifel $180, Citizens $180, BMO $187 (Top Pick maintained), Guggenheim $188, Scotiabank $190.
BofA did the big swing — upgraded from Underperform to Neutral, PT $75 → $170, and doubled their multiple basis from 4.5x to 9x FY27 EV/S. That's a capitulation on the model, even if they won't call it a buy. They cite growth re-acceleration, new product contribution, and a positive AI story.
The holdouts: TD Cowen at $175/Hold, citing competitive considerations. Mizuho at $165/Neutral, unconvinced the re-acceleration is durable. Everyone else is on the bus.
The AI narrative was already in the stock — Scotiabank upgraded back in July on the exact thesis that AI spend flows to identity. What's NEW:
1. AI agents are paying customers today, not a slide-deck story. Dozens of agent-related deals, several >$1M. One energy CISO adopted Okta for agents and grew spend by $1.5M. Reference deals visible: a large financial services firm and a $20B retailer modernizing identity stacks in 2026. Small numbers, but proof of a pipeline. 2. Suite-selling is the GTM motion now. Governance + privileged access + access management selling as one package. Emerging products = 30% of bookings with an average 40% ACV uplift. Land-and-expand on steroids. 3. Agentic AI is NOT in guidance. Multiple firms flag FY2028 as the monetization window. The market is getting the agentic kicker for free.
The seat-compression bear — AI agents replacing human seats, crushing per-seat identity revenue — gets answered by a consumption path. Canaccord's framing: mgmt already pre-empted the bear.
Bull: This is a re-acceleration with two engines. cRPO growth is 300bps ahead of revenue growth and accelerating for a third straight quarter — line of sight to revenue re-accel. New ACV +50% in the hardest comp of the year means H2 prints faster. Identity is the choke point for every agent that touches a system, and OKTA is the last independent at-scale platform — the PANW/CyberArk deal just set the scarcity value. Valuation (~28x CY27E EBITDA per Scotiabank, ~27x CY27E FCF per Canaccord) is rich but arguably fair for a 77% gross margin, re-accelerating platform with an untouched agentic kicker.
Bear: The move already happened. 85% in six months. 9x FY27 EV/S assumes the re-acceleration is durable — what if it's not? Mizuho's point: cRPO accelerating 2pts off a low base is stabilization, not structural re-acceleration. Agentic contribution is FY28 — 16 months out, and if it slips, there's no multiple support. TD Cowen quietly keeps a Hold on competitive considerations. And the one blemish: Q3 FCF guide came in slightly below consensus.
"The quarter was strong across almost every dimension... The bookings in the quarter were record all time for Q2... [and] a record all time outside of Q4." — Todd McKinnon, CEO (via Citizens)
"Management has arguably pre-empted the seat-compression bear case with a consumption path. The Palo Alto Networks and CyberArk transaction reinforced scarcity value for at-scale identity platforms that Okta's valuation doesn't fully reflect." — Kingsley Crane, Canaccord
"Artificial intelligence is not generating material contribution to bookings currently, though it is expanding the pipeline." — BMO
Identity is the agent's ID card. Every agent needs an identity, authorization, and a policy boundary — the identity layer is a tax on agentic AI, and OKTA is the purest public way to own it. This is the cleanest "AI is real but not in the numbers yet" demo in software. Canaccord frames the re-rating as catch-up to identity's "strategic centrality in an agentic enterprise." Trade it across to CRWD (workload identity), PANW (platform security), ZS (Zero Trust access). The agentic rotation is moving from model builders to the tooling that secures the agents. If OKTA prints a third straight cRPO acceleration in Q3, those $190-200 PTs start looking like a floor, not a ceiling.
Verdict: The AI security trade just got its fundamental proof point. CRWD printed net new ARR of $333M — +51% YoY vs $284M consensus — then raised FY27 net new ARR growth by 630bps, from 27.7% to 34%. That's not a beat-and-raise. That's a growth algorithm re-rating. The stock ran +61% YTD into the print (IGV -3%) and still cleared the bar by a mile.
And management explicitly flagged no deal pull-in or push-out. Said guidance philosophy hasn't changed — they don't guide to run the table. Then they raised 630bps anyway. That's the tell.
The guide math is staggering. Last quarter: +520bps/$52M raise to FY27 net new ARR. This quarter: +630bps/$64M. Cumulative: 1,150bps/$116M ABOVE THE ORIGINAL FY27 OUTLOOK. The implied Q4 net new ARR is $421M — a 26% step-up from this quarter. And that's their conservative number.
Eight firms, all constructive. PT range $230-$250, cluster at $240-250. Four at $250 (Mizuho, Cantor, Scotiabank, TD Cowen), two at $240 (Jefferies, Stifel), two at $230 (Citizens out, Baird neutral). Baird is the lone non-buy — even they admitted "execution continues to outpace expectations."
The consensus thesis: Mythos is a real demand catalyst, AIDR is the evidence, and the guide still has upside. Mizuho hands CRWD the strongest AI security offering set in the market. Scotiabank's CISO checks show enterprises moving "rapidly" on Mythos Preparedness. Jefferies expects momentum to strengthen from here.
"The combined guidance increases since CrowdStrike's initial fiscal 2027 outlook total 1,150 basis points or $116 million." — Stifel
"The quarter represents an inflection point for accelerated growth in coming quarters." — TD Cowen
"Customers are turning to CrowdStrike to modernize core security offerings to protect from AI threats and spend on securing AI usage with AIDR and Shield products." — Scotiabank
Bull: The second derivative is the story. Four straight quarters of ARR acceleration, five of revenue acceleration, and a guide that implies a sixth consecutive quarter of total ARR acceleration by Q4 — at $5.8B ARR scale. That's a platform inflection, not a product cycle. AIDR nearly tripling QoQ proves AI security attach is real, not narrative. Flex keeps consolidating workloads, driving record new-logo ARR and retention gains. Management has now raised FY27 net new ARR guidance by 1,150bps cumulatively, with no pull-in games and no guidance philosophy change. Record Q3 pipeline says the next raise is already in motion.
Bear: The stock is the position, not the company. +103% in six months. +61% YTD into a sector (IGV) down 3%. At $193B market cap, the market already pays for the inflection. Baird calls valuation "quite demanding" against an elevated expectations bar, particularly for cloud and identity. And the guide implies Q4 net new ARR of $421M — an enormous bogey. If the Mythos pipeline slips, if Flex discounting dents margins, if the AI security trade gets crowded enough to rotate — the multiple rewinds faster than the fundamentals catch up. Nobody questions the quality. The question is the price of perfection.
New: The print itself — +51% net new ARR vs $284M consensus, the 630bps raise, AIDR tripling, record pipeline, the acceleration streaks. Also new: management's explicit "no pull-in/push-out" and "guidance unchanged" commentary. That's them telling you the inflection is real, not engineered.
Known: The Mythos narrative, Falcon Flex consolidation, AI attack-surface expansion, the underpenetrated portfolio. The market already believed the story — that's why the stock doubled. What changed is validation: the numbers now prove the inflection, and the guide says it compounds.
"Management's confidence in a Mythos-driven inflection, with momentum expected to strengthen as the company moves further from the Mythos moment." — Jefferies
CRWD is the anchor for the entire AI security complex. Platform vendors — PANW, ZS, FTNT — ride the same "AI expands the attack surface, consolidate on the biggest platform" budget cycle. CRWD's record pipeline is their leading indicator.
For PMs, the positioning question matters more than the fundamentals. This is the most crowded long in software. The double in six months against a sector index down 3% is massive dispersion — CRWD IS the AI security consensus exposure. The print validates it, but the r/r has shifted: you're no longer buying a story, you're buying a story that must keep compounding. The $421M Q4 bogey is now the street's bogey.
Next catalyst: Fal.Con. Baird is "incrementally constructive heading to Fal.Con" — that's where the next Mythos/AI product drop lands, and this guide raise sets it up beautifully. Best fundamental print in security this year. Own the fundamentals, respect the crowd.
The $18B settlement just made Meta's "tobacco moment" go up in smoke. The legal tail that consumed the narrative for two years resolved for ~1% of the $1.47T market cap. The states had floated $200B. Meta's worst case: $1.4T. THE ACTUAL PRINT: $18B. Cheap. Now the debate resets to AI execution — where the stock already trades near trough multiples.
Mechanics get messy across filings — some say $12.7B guaranteed, others $11.66B; the contingency runs $5–5.3B if TikTok and YouTube adopt matching restrictions — but the direction is unambiguous. Nearly all state AG claims resolved. No admission of wrongdoing. 52 ATTORNEYS GENERAL ACROSS 48 STATES. The "tobacco moment" framing dies here.
The structural remedies matter more than the cash:
Caveat: personal-injury claims, school-district cases, and other non-AG litigation remain outstanding. And the EU DSA case on addictive design is still live. One cloud lifted, not the whole sky.
Buy ratings dominate. Visible PT cluster: $580 (BMO, Market Perform) to $886 (Rosenblatt Buy). Consensus lands ~$780 against a $576 print. BofA cites the broader Street range extending to $1,000. Evercore at $860 notes the stock had traded at 17x P/E — WITHIN 10% OF ITS THREE-YEAR TROUGH — before settling; it now prints 21x. Two fears drove that trough multiple: capex and youth-safety lawsuits. The settlement just removed one.
Bull: The overhang cleared, and BofA counts FIVE AI CATALYSTS in the next six months: personal AI product launch, top-tier LLM release, model licensing deals, an AI capacity deal, and messaging ad monetization. Street sentiment on Meta's AI is currently negative, per BofA — that's the setup. One credible personal AI demo and the multiple re-rates. Rosenblatt's frame: 16x EV/2026 EBITDA growing mid-20s. That's cheap for a quality compounder.
"The legal risk that had prompted media discussion of a 'tobacco moment' for Meta and social media largely goes up in smoke." — Rosenblatt
Bear: Needham's Laura Martin sees a strategy sprawl, not a strategy. Custom chips, data-center buildout, enterprise software, agents, model APIs, compute sales, ad tools, consumer assistants, smart glasses — each demands different products, customers, and sales motions. Spreading capital across all of them lowers the hit rate on any single one. BMO echoes: engagement headwinds, capex ROI unproven. The EU DSA case is the reminder that regulators aren't done with the product design playbook.
"By not concentrating its capital and free cash flow on the highest-return products and services, it raises the risk that management attention, engineering talent and shareholder capital are spread across too many things." — Needham
The contingent structure is the clever part. Meta's own bill shrinks if YouTube and TikTok adopt the same defaults — turning a legal cost into competitive pressure. BofA expects GOOGL's YouTube to face mounting pressure to join and pay into the state fund. Snap gets squeezed too, even though it wasn't named. The "social media is tobacco" narrative just lost its lead plaintiff — that's a read-through for the whole group, not just Meta.
AI calendar to watch: Hatch agent platform launches in weeks, Watermelon LLM in October. That's the next true catalyst. Tape context: LONG-ONLY FUNDS JUST DUMPED $44B IN SEMIS on AI sustainability worries — Meta's capex story runs through that same macro debate.
Bottom line: legal cloud lifted, valuation near trough, catalysts stacking. STOCK DOWN 22.7% OVER THE PAST YEAR. The bear case is now purely execution risk on too many fronts — a much better argument to be long against than a $1.4T lawsuit.
THE STREET JUST TOOK A BAT TO THE RECOVERY THESIS. INTU printed a solid Q4 beat, guided 23% EPS growth for FY27 — and the stock still gets slapped. Wolfe downgraded to Peerperform from Outperform. Truist and Wells Fargo cut PTs to $300. The rest of the cluster sits at $290-315. Only BMO ($412) and Mizuho ($430) hold Outperform. Shares at $343, DOWN 45% YTD off a $705 high. This stopped being a valuation debate months ago. It's a growth-machinery trust issue now.
Q4 was objectively solid: revenue $4.354B, +14% (2.1% beat). GBSG $3.424B, +14%, with midmarket products +38% and online accounting +20%. Credit Karma +16.5% vs 11.6% consensus on personal loans, auto insurance, and cards. Non-GAAP EPS $4.03 vs $3.58 consensus. Operating margin 33.3% vs 30.7% expected. On the quarter alone, this prints.
Then the guide killed it: FY27 revenue midpoint $23.396B — UP ~9.1% Y/Y VS 11.1% CONSENSUS. Tax segment revenue grows just 2% (Wolfe modeled >5%). New three-year Consumer CAGR target of 4-8%, down from the old TurboTax-specific 6-10%. GBSG three-year target slashed to 10-15% from 15-20%. Management touts 23% EPS growth and durable high-teens over the medium term. But the revenue engine is visibly downshifting, and the Street is pricing the guide, not the spin.
Wolfe's downgrade nails the core problem: the downmarket push in both QuickBooks Online and Tax to drive customer growth and monetization will take time to play out, and there are no visible catalysts. Truist frames INTU as an execution story after recent missteps, with AI-native competitors coming after TurboTax DIY. Wells Fargo flags TurboTax losing price-sensitive DIY filers to cheaper alternatives. The through-line: management is chasing the low end of a commoditizing category, trading pricing power for volume — and the guide just confirmed the trade-off.
"The turnaround strategy of pushing downmarket in both QuickBooks Online and Tax to drive customer growth and monetization will take time to play out. We see no clear catalysts and increased uncertainty for the shares." — Wolfe Research
Piper adds the credibility angle: INTU needs to rebuild trust after the Q3 tax miss, and that requires time and steady execution. 45% down YTD and downgrades keep rolling in — that's not a dip. That's a de-rating on structural concerns.
81% gross margin. Perfect Piotroski Score of 9. 9% free cash flow yield. FY27 EPS guided UP 23% with high-teens medium-term commitment. BMO and Mizuho see 25%+ upside from here. The bull argument: the market is pricing a broken franchise over a self-inflicted transition, and 81% GM businesses that compound FCF at high-teens don't stay in the penalty box forever. Credit Karma re-accelerated. Midmarket still prints +38%. The portfolio isn't broken — the tax engine is sputtering.
Verdict: BOX is the quiet grind finally getting paid for it. FIFTH STRAIGHT QUARTER of accelerating constant-currency revenue growth (11% cc vs 10% last qtr), NRR AT A 13-QUARTER HIGH (106%), and the AI narrative is showing up in actual attach, not slideware. Stock's up 38% in six months, sitting near its 52-week high ($33.88), and still trades at 12X CY27 FCF vs 18X for growth peers. That's the bull case in one sentence.
Q2 print: revenue $321.1M vs $319.33M expected, EPS $0.40 in line. Modest beat — the real story is rate of change. BILLINGS ACCELERATED TO +16% CC from +13%. NRR up another point to 106%, SECOND CONSECUTIVE QUARTER of improvement — the best reading in 13 quarters. Management raised FY27 revenue guidance $10M (+0.8%), implying a stronger 2H.
Enterprise Advanced is the engine: larger deployments, seat expansion, HIGHER PRICE PER SEAT. That's a volume-plus-price story, far more durable than discount-driven seat adds. (One wrinkle: DA Davidson's EPS estimates reflect a slightly lower gross margin outlook, though 79.6% GM is still elite.)
This is where it gets interesting. THREE BUYS, ONE OBSTINATE BEAR: DA Davidson $50 (from $45), BofA $42 (from $39), UBS $37 (from $29) — and RBC holding Underperform at $26. Nearly a 2x spread between high and low target on a stock at $33. Rare to see that much disagreement this deep into a re-rating.
BofA makes the AI call that matters:
"Box is one of the few applications vendors demonstrating visible AI product momentum."
And the follow-through: Street estimates at 8.7%/8.8% growth for FY28/FY29 look increasingly conservative if the 10-15% long-term algorithm is real. DA Davidson's math: $50 target = 18x CY27 FCF, in line with growth peers — but the stock still sits at a 33% discount to that group. That's the r/r. Even UBS, the most conservative of the bulls, jumped PT by 28% ($29→$37).
RBC's bear case isn't about the quarter — they concede non-GAAP op margin beat and billings came in ahead. It's about the moat. Box lives in the Microsoft (SharePoint/OneDrive) and Google Drive kill zone. Content collaboration is table stakes. NRR of 106% is respectable but a far cry from the 115-120%+ you see in true platform names. Fair point. But at 12x forward FCF, the market's already pricing in a pedestrian outcome, not a Snowflake multiple.
Positioning improving but not crowded. Six-month run got it to a 52-week high; at $33, it's still ~25-50% below the bull cluster. THE 106% NRR IS THE SINGLE METRIC THAT MATTERS. If it holds or ticks up again, $42 (BofA base case) gets revisited fast. If it rolls over, RBC's $26 starts looking like the honest number. Watch the beat-and-raise cadence next quarter — and the AI attach commentary is the swing factor.
Semtech is the purest AI connectivity compounder on the board that isn't NVDLA or MRVL. Northland finally got off the sidelines — upgraded to Outperform with $182 PT — while BMO keeps its Outperform but at a far more conservative $155. Same thesis, different conviction levels. That spread ($155-$230 across the Street) tells you the debate is valuation, not story.
BMO's the most useful frame here. Semtech's moving from selling TIAs/drivers (cheap silicon components) to full optical modules. That's not incremental — that's a step-function change in TAM and content capture.
"Semtech is shifting from a TIAs/Drivers components maker into a complete player, combining legacy silicon products with optical components within a module."
The numbers back it up. Content per 3.2T module goes from high-single digits to $80-90 — call it a 10x uplift. BMO thinks the transition takes ~18 months and sees growth accelerate in FQ4. That timeline is the gating item. If it slips, the multiple compresses.
Northland's angle: connectivity is the AI bottleneck on power and performance — not compute. Semtech's taking share in BOTH copper and optical. That's the kind of share story PMs pay up for.
FQ2 print was clean: EPS $0.71 vs $0.61 bogey, revenue $342M vs $328.6M est. That's the tenth straight quarter of revenue growth — momentum is real. FQ3 guide also beat by a mile: midpoint 13.6% above prior revenue estimates, EPS $0.32 better.
The mix shift is doing the heavy lifting. Data center now 30% of revenue; Northland sees 44% by end of 2027. LoRa's compounding alongside, and the cellular module divestiture helps push gross margin into the mid-60s. That's operating leverage breeding more operating leverage.
Rest of the Street is in the same camp: UBS and Benchmark at $230, Needham at $200, Stifel at $188. All Buy. Northland's $182 is late to the party but at least showed up. BMO at $155 is the last honest bull — they raised estimates meaningfully but kept the PT conservative.
Bull: This is a 10x content-per-module story with data center mix going from 30% to 44% and gross margins heading to mid-60s. Revenue growth of ~18% LTM supports it. Connectivity — not compute — is the real AI bottleneck, and Semtech wins in copper AND optical. Compounder with a catalyst schedule.
Bear: Stock's up 142% over the past year, 56% in six months. InvestingPro flags it as overvalued vs fair value. BMO's $155 PT implies ~11% upside from $139 — that's a terrible r/r for a stock that's already repriced. If the 3.2T module ramp slips, the guide beat is already in the number, and the multiple compresses fast.
FQ4 acceleration is BMO's call — that's the confirmation signal. Also watching the actual module design win announcements (names matter), and whether GM hits the mid-60s on schedule. The $230 crowd is pricing perfection; the $155 crowd is pricing an 18-month transition with slippage risk. Truth lands in between — but this is a real AI connectivity play, not a beta fake-out. Just don't chase it blind on a 142% up-year without respecting the timeline risk.
BOTH SHOPS RAISED after a Q4 that came in hot — BofA to $78 (Buy) from $65, Wells to $65 (Equal Weight) from $55. Stock sits at $65.39. So Wells says "fully valued here," BofA sees another 20%. The gap between those two targets IS the debate.
THE QUARTER: REVENUE $757M, +16% Y/Y, 2% ABOVE THE HIGH END. ARR $2.549B, +16%, ACCELERATING SEQUENTIALLY. NRR 106%. Bookings grew high teens — well ahead of the 12% revenue print. That's the metric a PM wants to see: demand running ahead of revenue.
BofA's key checks — no unusual pull-ins, no future-start-date catch-up. The beat is clean. Not borrowed from next year.
Bull: 3,000+ NEW LOGOS in FY26, large competitive wins, external storage now real (bookings up sharply QoQ, multiple seven-figure ACV deals, NetApp and Lenovo added to Dell/Everpure). NC2 pulling share partly BECAUSE of hardware constraints. ARR acceleration plus margin expansion equals compounder math.
Bear: Wells isn't wrong — stock up 71% in six months, PT at the current price. Hardware supply constraints push FY27 orders into future-start dates, which makes revenue conversion lumpy. The beat is good. The tape already knows.
Hardware constraints are the only real debate. Nutanix expects a GREATER PERCENTAGE OF FY27 ORDERS WITH FUTURE START DATES vs FY26. Translation: demand is strong (net new ARR $114M QoQ vs $79M trailing four-quarter average), but timing gets messier. That's a pushout, not a loss — as long as you believe the supply chain heals.
BofA's the strongest bull:
"Core hyperconverged infrastructure remains the largest revenue driver, while external storage, NC2, cloud-native, database and early AI offerings expand the company's addressable market."
Simple r/r: you pay up for the clean beat and the 16% grower with 87% gross margins, or you wait for the hardware noise to clear. BofA says buy the noise. Wells says it's priced.
TWO CURVES, ONE STOCK: ENTERPRISE +7.8% (11-QUARTER HIGH), ONLINE ~1% AND FADING. The Street's answer is two Neutrals (Cantor $104, UBS $115), a couple bulls (RBC $130, Benchmark $125), and a middle cluster (Bernstein $108, KeyBanc Sector Weight). Nobody is paying up. For once, the tape agrees with the analysts.
Enterprise revenue accelerated to +7.8% y/y — fastest in three years — and now prints 62% of total sales. RPOs accelerated a fourth straight quarter, +14%. ZCX ARR grew high-double digits with record seven-figure deals. And the number that matters most: NINE OF THE TOP TEN TRANSACTIONS INCLUDED PAID AI FEATURES. That's not a maybe-there's-demand story. That's AI attach at the point of sale.
The bear case lives on the other side of the ledger. Online growth decelerated from 3% to ~1% y/y. Management blamed "AI-driven changes in customer discovery" — plain English: AI search is rerouting demand away from Zoom's free funnel. They cut 2H Online guidance to flat from slightly positive. That's the bogey. UBS pegs the drag at $10-20M of 2H revenue that Enterprise strength and the Common Room acquisition only partially offset. Full-year guide held at ~4% constant currency, which is a tell: management won't bank the enterprise momentum.
Cantor's framing is the sharpest:
"AI-driven changes in customer discovery pressured online customer acquisition, leading to a softer second-half fiscal 2027 guidance."
Gross margin took a hit from elevated AI usage and trials (still 77.66% LTM, so let's not cry). FCF guide went UP ~$80M to ~$1.8B — but UBS flags ~$40M of that is just extending asset life in one data center by two years. Accounting, not earnings power.
Bull: Enterprise is inflecting. AI attach is real and paid. ZVA customers +256%, Workplace AI MAUs +125%, FCF upgraded. RBC at $130 and Benchmark at $125 see a re-rating the moment the Street stops staring at the Online line.
Bear: Online is structurally broken — AI changed discovery, and that's not a fixable sales problem. AI usage now pressures gross margins, adding a cost line that doesn't go away. The guide held at ~4% DESPITE enterprise strength = management has zero confidence in the 2H ramp. UBS holds Neutral at $115. Cantor holds Neutral at $104. The trade works only if you believe the Anthropic stake is real value, and nobody is modeling that in.
Cantor: 4.5x CY27 revenue, or ~3x once you back out the Anthropic stake at a potential $2T IPO valuation. UBS: ~11x CY27 EV/FCF, adjusted for the $3.13B book value on that stake. Stock trades at 14.89x P/E with a PEG of 0.05 — a number so low it's telling you consensus growth is priced at zero. Shares are +33.6% in six months. Easy money: made. But the multiple still leaves room if Enterprise holds 8% and Online flattens.
This is a good business inside a broken narrative. Enterprise proves the product still lands and expands. Online proves the customer acquisition model is broken. Until that second curve stabilizes, Neutral is the right r/r. But the 9-of-10 paid AI stat is a weapon. If Online goes flat-and-stable and Enterprise holds 8%, the bears run out of ammo — and the Anthropic stake is the kind of catalyst that turns a Neutral into a squeeze. Watch the 2H prints like a hawk.
VEEV IS THE ONLY LIFE SCIENCES SOFTWARE NAME THAT MATTERS RIGHT NOW. Analysts aren't just tweaking numbers — they're signaling the Salesforce win-back story has legs. Jefferies goes to $295 from $250, Needham to $310 from $270. Both Buy. That's a $295-$310 PT cluster off a prior $250-$270 band. Stock at $244.91, up 35% in six months, and the Street thinks there's another 20-25% in it.
Q2 FY27 was a clean beat and raise. Adjusted EPS $2.35 vs $2.22 bogey, revenue $928M vs $905.4M expected. Gross margin 75% — that's the moat. Management raised full-year guidance. The market's already paid up, but the rate-of-change is positive again.
The headline: THREE CRM WINS, INCLUDING TWO TOP-20 PHARMA — ELI LILLY AND BIOGEN — PLUS REGENERON JUST OUTSIDE THE CLUB. That's not a fluke quarter. That's a land-grab signal. Vault CRM deployments hit 180 go-lives. Management now talks about winning the remaining two top-20 holdouts and potential win-backs from Salesforce over the next two years.
The AI angle is early but real. Needham flags "early demand" for Falcon, Jefferies says "stronger-than-expected interest." Nobody's putting numbers on it yet, but the narrative matters — it keeps VEEV in the AI trade conversation without needing Amazon-scale capex.
Bull case: The Salesforce displacement cycle is accelerating, R&D products are healthy, and 75% gross margins on 16% revenue growth makes this a compounding machine. Management keeps raising the bar and clearing it.
Bear case: The stock already ran 35%. You're paying for a top-20 sweep that may take two years, and Crossix is good but not a new growth engine. If the next two top-20 pharma decisions slip, the multiple compresses fast.
Needham nailed the punchline:
"The recent success gives management increased confidence in winning the remaining two top-20 companies that have not yet made a decision, as well as potential top-20 win backs over the next two years."
That's the whole thesis in one sentence. VEEV is no longer defending its CRM turf — it's on offense. And with 180 Vault CRM go-lives, the switching costs just keep stacking. Buy the dip, but don't chase the first green candle. Better entry on the next guide-up.
Verdict: Same print, two very different reads — and a 28% spread between targets. Cantor cuts PT to $476 from $654 (still Overweight — that's not nothing after a 27% haircut). Raymond James parks at Strong Buy, $610 PT, unchanged. The market already voted: -22% IN ONE WEEK to $311. But this looks more like a guidance re-rating than a thesis break.
Clean beat, ugly tape. DY printed $5.29 vs $4.70 bogey on $2.0B REVENUE. Raised full-year outlook. None of that mattered — the forward guide did the damage: lower FY27 Communications guide, FQ3 below Street, margin pressure in Communications.
The scapegoat is the $150M wireless revenue shift into FY2028. Management says timing, not lost scope. Wireless is <5% of the business, so the panic math gets weird fast. But margins are a real conversation — that's not a timing shift, that's a profitability question.
Cantor actually picked up the phone — spoke with the CEO and IR post-print — and still cut the target. Management pushed back hard on the fiber-weakness narrative. Says the broader Communications business is executing across fiber-to-the-home, service/maintenance, and long-haul/middle-mile. The $150M isn't gone, just later. Cantor's move is a "we believe you, but the market won't pay the same multiple for less near-term clarity" cut — rating stays, target compresses.
Raymond James is unbothered. Strong Buy, $610 PT. They're leaning on backlog growth and NEW LONG-HAUL CUSTOMERS added since quarter close. Their TAM: $20B+ for AI fiber builds — and they think the opportunity is STRONGER than previously assumed. The kicker:
"Fiber routes have been running out of physical fibers for sale, driving significant need for new construction for growth and expansion."
That's the bull case in one sentence. Existing fiber is full. You can't splice your way to capacity. You have to build — and these are complex builds relative to FTTH, which is exactly where DY's crews earn their keep.
Bull: Beat-and-dump on a timing shift is a gift. Demand is intact — AI data centers need long-haul and middle-mile fiber, plus retrofit work for higher power density. Backlog up, new customers post-quarter, 38% REVENUE GROWTH LTM to $6.88B with Street at 37% for FY27. The $150M shows up next year. Buy the confusion.
Bear: A beat that gets dragged 22% is a tell. When a company pushes revenue out AND guides margins down, the market hears "the easy growth is behind us." Cantor's 27% PT cut isn't noise. $476 vs $610 — that spread is the market's honest uncertainty about FY27. Don't catch this knife until FQ3 confirms the trajectory.
This is now a debate about the guide, not the thesis. Both analysts sign up for the AI fiber demand story. The disagreement is whether management's "timing, not lost scope" framing holds. FQ3 print is the tiebreaker. Until then, the stock is a contested re-rate — with a $610 target sitting ~96% ABOVE THE CURRENT PRICE, the r/r is asymmetric if Raymond James is right. That's a big if. But that's what a 28% target spread looks like when conviction and caution collide.
Evercore ISI keeps the Outperform / $150 PT after CSCO expands its Secure AI Factory with NVIDIA — this time via Supermicro. That fills the one box CSCO was missing in the AI story: rack-scale compute for neocloud and sovereign deals where the customer wants a full-rack win, not just the network. Orders open October 2026.
The "first NVIDIA partner to deliver an NCP-compliant reference architecture on partner-developed networking" bit is the real meat — CSCO gets to span its own Silicon One AND Spectrum-X silicon under the Nexus One architecture, which is a positioning unlock, not just a reseller deal. Also clever framing on supply chain: pairing with SMCI is a de-risking play when component availability is the gating factor.
Evercore views the partnership as an extension of Cisco’s AI infrastructure strategy that improves its position in neocloud and sovereign deals, where the company can now deliver on compute capabilities and enable more full-rack wins.
One article, one take — this is steady-as-she-goes for the bull case, but it's incremental, not transformative. The market already knows CSCO is selling AI networking. Now they're selling the whole cabinet. That's a TAM expansion, just not one that shows up in the model until FY27. Not sure we need to chase this one on the news — it's a confirmation print, not a catalyst.
THE SETUP IS SIMPLE: BEAT AND RAISE, OR THE STOCK GETS BODIED. DA Davidson bumps PT to $465 from $375 into the Sept 1 print, but that's the conservative end of the street now. Evercore's at $525, Citizens at $519, Goldman at $453. The consensus buy thesis is clicking — Atlas is 75% of revenue and everyone expects a beat.
DA MODEL: ATLAS GROWTH ~28-29% YoY vs. 26% GUIDANCE. That's the bogey. Some PMs are positioning for 30% print, but management has spent two quarters conditioning the buy-side for a 2-3pp upside range. The nuance here — DA thinks the guide-up matters more than the print. H2 Atlas AND Enterprise Advanced guidance both going higher. Vector Search demand commentary is the catalyst on the call.
"Investor conversations throughout the quarter have indicated acceptance of the 2 to 3 percentage point upside range over the last couple quarters that management has emphasized."
Options pricing ~14% move post-earnings. That feels wide for a name already up 89% on the year. R/R skews long only if you believe the guide-up is real — the stock's now trading like every quarter is a prove-it moment. Goldman's modeling >29% Atlas, so if DA is right and it prints 28-29%, the market might shrug. The bull case lives in the H2 raise.
The government is the entire story and it hasn't broken yet. William Blair reiterates Outperform on the Maven Smart System expansion — and their contract tracker is about as granular as it gets. This is no longer a growth narrative, it's a budget capture narrative. The Pentagon literally titled a memo "Funding Palantir."
US gov revenue growth ACCELERATED TO 90% IN Q2 from 5% in Q4 2023. Total revenue growth 79% LTM, gross margins 84.8%, market cap ~$421B. Blair flags MSS as Palantir's largest overall contract, trending toward a BILLION-DOLLAR annual revenue run-rate. Deputy Secretary of War Feinberg called for an extra $244M between now and March 2027. The FY27 budget request: $2.3B for MSS + Joint Fires Network, up significantly from prior years.
MSS is also becoming program-of-record by end of September. That's institutionalized demand.
"Funding Palantir" — Deputy Secretary of War Steve Feinberg's August 4 memo, calling for a $244 million funding increase through March 2027.
The post-Q2 analyst cluster is tightening: UBS to $220 on 93% growth acceleration, Truist to $223 on sovereign AI, Phillip Sec to $215. Benchmark sits on Hold, nodding at the Rule of 155. PTs converge in the $215-223 zone. But Blair's the one with the gov contract data and they're not chasing with a PT — they're just saying the floor keeps rising.
Blair's main bear: LLMs commoditize Palantir's core. Their own forward-deployed engineers could leave and build similar apps on LLM platforms for pennies. That's the real r/r break — not valuation, not multiple compression, but the code becoming a commodity.
Political risk is secondary but real: MSS rollout could slow under a Democratic regime. Counterpoint? Once a program hits program-of-record and eats $2.3B of budget, it's sticky. Defense procurement doesn't reverse easily.
Net: the machine keeps eating the federal budget. Hold the shares, watch the contract announcements.
DA Davidson bumps PT to $80 from $60 but holds Neutral — target's basically the spot price ($79.92). Usage trends look solid (strong customer commitments last quarter, healthy consumption demand from peers), but guidance already prices in the acceleration, so the bar into tomorrow's print is high. Add product-leader departures and restructuring noise, and the r/r is mediocre. Street's split: Rosenblatt/Stifel/Cantor at $83/$90/$91, while Morgan Stanley cut to Equalweight doubting the inflection happens at all. STOCK UP ~32% IN A MONTH and fading into the report — expectations are the enemy.
Guidance already incorporates an acceleration of growth, potentially limiting upside.
TD Cowen jacks PT to $42 from $29 — a $13 hike — but keeps Hold. Stock sits at $41.31. Translation: they see the momentum, they just won't chase it at these levels. Neither should you, necessarily.
Q2 earnings prints Sept 1. Guggenheim modeling 19% revenue growth — that's a 400bps decel from last year's 29%. Management guided conservative into the print. TD Cowen's partner checks look consistent with Q1, so a beat is in the base case.
MARGINS 87% GROSS. STOCK +57% IN SIX MONTHS. The tape is hot. The question isn't whether they beat — it's whether the guide keeps the rally alive. Guggenheim sees Q3 in-line and FY27 trimmed to 17% growth at the midpoint.
Bull: developer hiring trends positive, partner checks steady, and 19.2 ships AI-powered dependency scanning (public beta) to keep the product narrative fresh.
Bear: competitive backdrop is shifting fast. That's the medium-term risk TD Cowen flags, and it's the reason you're seeing Hold ratings and $40-$42 PTs instead of a race higher.
"The firm sees a quickly changing competitive backdrop carrying medium-term risks for GitLab."
Reality check: PTs are catching up to price, not leading it. UBS at $40, TD Cowen at $42, stock at $41. This is a balanced tape — fine for holders, not screaming upside for new money. If you're long into Sept 1, you're betting guide > beat. That's the whole ballgame.
Bernstein holds Market Perform / $282 PT — a real 29% above the tape, which tells you this is "good story, rich price" rather than "no story." BE prints $218.21, UP 151% YTD AND 329% OVER THE PAST YEAR. That move is almost entirely narrative: current EV/EBITDA sits at ~154x while Bernstein's PT math uses 41x on blended 2H27/1H28 EBITDA. The stock is already priced for years of flawless execution — any stumble hits hard.
The demand thesis has teeth though. Data center moratoriums plus large-load grid interconnection delays keep pushing hyperscalers toward islanded power. Bernstein frames the whole debate as four questions: how many GW of data center demand this decade, how much actually goes behind-the-meter, whether BE captures meaningful share, and whether the valuation reflects it. Q2 answered part of it — EBITDA $253M vs $152M consensus, REVENUE $1.07B +166% YOY — but the Street reaction stayed split. Mizuho and Clear Street turned positive, Truist cut to $218 on demand concerns, Oppenheimer sat on its hands with a Perform. A beat-and-raise that splits the tape this hard is not a clean long.
"Data center development moratoriums and delays in obtaining large-load grid connections continue to support demand for islanded power solutions."
That's the bull case in one line. The bear case: at ~154x trailing EBITDA, you're not getting paid to be right — only to be more right than consensus already is.
Verdict: Raise PT by $6 at TD Cowen (Buy, $36 from $30) and the message is the "why" — Braze is getting back to a cleaner beat-and-raise cadence, and AI adoption is the accelerant.
Shares already up 62% over six months, PLUS 25% since Q1 — high bar into the Sept 8 print. TD Cowen reads Twilio and Klaviyo results as encouraging read-throughs, with new AI adoption ramping across the customer engagement layer. The intra-quarter line is the whole ballgame:
"We think there were favorable developments intra-qtr which should help BRZE get back onto a cleaner qtr in terms of rev beat & GM stability vs. Street ests."
The street's all circling the same story — BTIG at $35, Goldman init Buy $34 — enterprise wins plus AI monetization driving next year's product cycle. But the last quarter exposed the wrinkle: Braze raised top-line guidance to 22% YoY (consensus 20%), yet subscription revenue slipped below Street while Professional Services overdelivered by $6M. The "clean quarter" narrative depends entirely on mix. Sept 8 shows us if subscription health is real, or if it's another pro-services patch job. The 62% run makes that distinction worth a lot.
TD Cowen stepping in front of tomorrow's print. PT to $13.50 from $10.00 (Buy). Expects a modest beat and a bullish usage-model update — that transition already 10% of ARR last quarter. Stock UP 82% over six months, more than doubled off lows, but still DOWN 6% YTD vs EMCLOUD +14%. Catch-up trade has legs if they confirm growth acceleration to mid-single digits.
Multiple expansion is the whole thesis: 7x EV/FY27 FCF to 8x on the new PT. For 85% gross margins that's not demanding — but MS sits Underweight at $9.00, arguing AI-native entrants kill the moat before the usage pivot pays off. Two sides of the same coin: pay 7x for a mid-single grower, or pay 7x for a company about to get disrupted.
"The firm expects multiple expansion as the usage-based model gains traction and growth accelerates to mid-single digits."
That's the bull case in one line. Tomorrow's print tells you if it's real.
Truist bumps the target to $20 from $19 and the stock just blows through it — trading $21.43, ABOVE THE NEW PRICE TARGET. Hold stays. When the street's most cautious voice is this far behind the tape, the narrative's already moved.
REVENUE $161M (+8% YOY) — beat by ~$2M. ADJUSTED EPS $0.05 vs $0.2658 expected — horrid bottom-line print. But NON-GAAP OP INCOME $40.8M clears both Truist and consensus. The divergence tells you the street's anchored on the operating line, and that line is solid.
Pricing transition is the whole ballgame. 48% OF ACV NOW SITS ON THE NEW MODEL — ahead of the four-year timeline. Enterprise customers renewing earlier. AI adoption inflecting. US mortgage down 1% and still the sore thumb, but nothing that breaks the thesis.
Bulls cluster at $25 — KBW, Needham, Citizens. Needham cites subscription growth and the FY27 guide raise. KBW flags the op income beat. Citizens credits pricing transition progress. Truist wants "further subscription revenue reacceleration" before jumping off Hold.
Enterprise customers are renewing earlier and Banking Advisor and AI usage are showing positive dynamics.
Stock's +25% in six months. The chasm between Truist's $20 Hold and the $25 bull cluster says the easy money's priced. Bull case runs on execution against the pricing timeline — and so far, nCino's delivering.
Baird upgrades to Outperform (PT $560 vs $558 prior — target barely moves, the rating is the statement). Thesis: FY26 is the turnaround year and FY27 returns to DOUBLE-DIGIT ORGANIC GROWTH with upside to both revenue and FCF estimates. That's the whole ballgame — the stock entered FY26 at 35x, got abandoned when the turnaround didn't materialize fast enough, and now sits at low-20s while the rest of semis ran. Baird's call is that the de-rating is over, not still in motion.
September 30 investor day is the catalyst — expect the FY27+ financial framework plus the growth story across EDA software, Design IP, and Ansys. Q3 FY26 was a clean beat ($3.91 vs $3.67 est; $2.48B vs $2.44B) and they raised the full-year guide. Stock still faded after hours, which tells you expectations had run hot. Not sure we read too much into that — the print was solid, the guide was better, and the multiple is already compressed.
"We would be surprised if this development leads to multiple compression from the current low-20 times price-to-earnings ratio instead of lifting the stock."
The quality anchor is the margin profile: 82.6% GROSS MARGIN, 39.5% LTM REVENUE GROWTH. That's a compounder trading at a cyclical-low P/E — Baird's just willing to call it. The risk is if the September investor day underwhelms on the FY27 framework; then you're back to waiting on IP engagements and Multiphysics Fusion commercialization. But the r/r skews fine here.
TWLO ISN'T YOUR FATHER'S CPaaS ANYMORE. Citizens re-ups Market Outperform and $275 this morning, and the Street's PT cluster has converged at $260-280 (Needham $280, Rosenblatt/Stifel $275, TD Cowen $260) — all post-Q2, all on the same AI voice thesis.
The rate of change is the story: VOICE REVENUE +20% Y/Y, SEVENTH CONSECUTIVE QUARTER OF ACCELERATION. That's not a headline trade — that's compounding. Mgmt says strength is broad-based across all channels, which matters because it kills the "one big customer" bear case. Organic growth 17%, FCF margin 24%, LTM revenue $5.57B, and 23 analysts just revised numbers UP into the print.
"Voice revenue growing over 20% year over year, marking its seventh consecutive quarter of acceleration."
The bull case writes itself: comms layer is the data moat, AI voice is the TAM expander, mgmt (Shipchandler/Viggiano/Wyatt) gets credit for the operating discipline. The bear case is valuation math — $35B mcap against a $119B 2028 TAM that's mgmt's own number. But with estimates still rising, short the acceleration at your own peril.
Guggenheim's the loudest bull — PT to $210 from $180, Buy maintained, and they're basically calling the Sep 3 FQ4 print a low-bar setup. STOCK'S AT $191, and the Street is bracing for a guide-down. Guggenheim says the market's wrong: consensus implies a momentum collapse that isn't coming. They see FQ4 at least meeting, with FY27 ARR guidance STARTING AT/ABOVE $1.45B (+17.9% YoY) and beat-and-raise potential as the year progresses.
The bull case hinges on cloud new business and migrations, especially after FQ3's deal-timing mess ($1.147B ARR, +19%, but just $26M net new — light). Bears (Wells Fargo, $190 UW) say the deceleration is real. Bulls (Stifel $225, Piper OW $210) say lumpy, not broken. That's the whole debate.
"Consensus implies a significant decline in business momentum that is unlikely to transpire."
AI is the side narrative — every P&C customer conversation eventually lands on how to deploy the tech inside insurance workflows, and Guidewire sits on the operational backbone. ProNavigator's live at Germania Mutual. Not a quarter driver, but it keeps the multiple anchored. Net: attractive r/r into the print, but execution has to show up in the guide.
Wolfe just made 2027 its year for Alphabet — reiterating Outperform with a $460 PT and naming it a top pick. The bull case lives in GCP: Wolfe models Q3 growth at 125% YoY vs Street at 87%. THAT'S A 38-POINT GAP. If Wolfe is right, the entire estimate path is too low.
The firm raised 2027 revenue +10% to $595B and EPS +6% to $15.89. At 17.14x trailing with a 0.15 PEG, the market's still pricing Google like a slow grower after a 65% run (value multiple, compounder fundamentals). Citizens echoed the sentiment — $515 PT, same cloud/AI model momentum thesis.
"The firm stated it does not believe it is too early to make a 2027 stock pick."
No hedging there. PMs who wait for confirmation pay up.
UBS keeps Buy and $275 PT on ACN at $182 (14.96x — cheap for the quality). The McCoy pickup is Dutch SAP consultancy, ninth deal in FQ4, and it plugs straight into Accenture Edge — the new $300M-$3B revenue mid-market push. They're at 33 announced deals YTD vs 36 for ALL of FY25. The M&A machine is lapping last year's pace with a quarter to spare, and the market's treating it like an also-ran.
The tension worth watching: ACN tripled FY26 acquisition spend to ~$9B from the initial $3B (vs $1.5B in FY25), but UBS flags the 150bps inorganic revenue contribution to FY26 is UNCHANGED despite the surge. That's a capital allocation efficiency question, not a thesis breaker — $12.6B levered FCF covers the checks — but it says the incremental dollar is buying less growth than the original plan implied.
"The 150 basis point inorganic contribution to 2026 revenue remained unchanged over the course of the year despite the increased spending, UBS noted."
Also stacking backlog: €200M NATO contract (7-year, 29K users) plus a Google Cloud mid-market AI suite tied to Edge. Buying distribution while selling the platform — classic ACN. The risk isn't the thesis, it's whether $9B of M&A delivers the compounding, or just the revenue.
SEPT 1 IS THE ONLY THING THAT MATTERS. Stock's up 127.5% in six months, and Davidson's $345 PT is basically spot ($339.05) — the low end of a bullish field (BofA $420, Benchmark $400, JPMorgan $384, BTIG $380). That dispersion tells you everything: nobody's getting caught without a Buy, but nobody agrees on the number.
FQ4 beats on all key metrics, FY27 revenue and ARR guide above consensus. The tell: Davidson sees adj FCF margin guided BELOW 38% consensus, trimming their own to 37.3%. Platform momentum (Mythos, AI) is real but costs margin.
"Mythos and AI-driven upside must be evident in the results and guidance for shares to work post-earnings given recent outperformance."
Options imply an 8.6% move. High bar on organic net new ARR. Stock needs the beat AND the AI narrative in the guide — a clean quarter won't cut it at this valuation.
BofA starts it a Buy with a $70 target — ~45% upside from $48.40, and that's after a 99% run in the last year. This is a look-through call: the market's pricing the legacy packaging business, not the transition. BofA says the shift to Advanced Products, 2.5D, HDFO-RDL/bridge, co-packaged optics, and test isn't fully in the numbers. Neither is the Arizona facility's strategic value (the "onshore AI packaging" angle nobody else can replicate right now).
"The market does not fully reflect the company's shift toward Advanced Products, its expanding role in 2.5D packaging, HDFO-RDL/bridge, co-packaged optics and test, and the strategic value of its upcoming Arizona facility."
EPS trajectory is the headline math: $1.51 (2025) → $3.41 (2028), a 31% CAGR. PEG of 0.26 on that growth makes the multiple look silly cheap. Target's 21x 2028 EPS — above consensus, but not heroic if utilization keeps climbing.
The Q2 print supports the story. EPS $0.70 vs $0.47 consensus, revenue $1.9B (+26% y/y). Gross margin popped on mix and utilization. Stock still faded after earnings — market got spooked on near-term optics. BofA says that's the wrong frame. With AI packaging supply still tight and US regionalization just getting started, the 2026 concerns are bogeys, not thesis-breakers.
Bull case: mix shift + Arizona optionality = re-rating. Bear case: 99% in a year means a lot of good news already sits in the tape, and 21x 2028 is a big multiple to put on a semi-services name if AI capex wobbles. Right now the r/r skews positive.
MU — NVDA confirmed memory's pricing power: 20% price hike + 2.5pt GM guide-down implies HBM UP ~50%, and TrendForce sees contract prices UP ANOTHER 70-140%. 2027 memory revenue estimates look low. De-spec'ing stores demand, doesn't kill it — a correction is hard to engineer. 2028 is the scheduled top (capacity response lands same time as SK hynix Indiana), CXMT the slow-burn bear.
SNDK — Kioxia's ¥1T ($6.3B) Iwate fab adds a 2029 supply leg, but NAND stays tight through the cycle. Samsung's HBF creates a second growth curve between HBM and LPDDR. NVDA's memory bottleneck read-through extends straight into NAND. Positive with a 2029 supply-watch sticker.
WDC — Same NAND read-through as SNDK, cheaper beta. Memory has been the highest-conviction long; WDC gives you the tightening story with HDD upside on AI storage. Nothing fancy, just leverage.
INTC — EMIB is a confirmed CoWoS rival: Google and MediaTek hit technical, yield, and cost targets, Malaysia capacity ramps fast. Management targets 40% GM / 30% OPM in packaging — a back-end entry that doesn't require winning the wafer race. 18A yields track ahead, and the CFO finally admitted clean-room needs (MS sees $20B tool adds next year). Vera Rubin's rack-scale economics squeeze the CPU side — packaging wins offset, not replace.
TSM — Clearest direct beneficiary of NVDA's supply-constrained 70% guide — content per GW rises to $40B with Vera Rubin. Apple M6 shifts to dual packaging (SoIC-MH + WMCM), capacity doubling to 120k+ wpm by 2027. Intel EMIB is a confirmed second source — threatens the monopoly, not this cycle.
ASML — NVDA's ~30pt gap between customer demand growth and deliverable growth is a standing invitation for capacity adds. Logic, HBM, packaging all need more equipment. Highest-leverage lithography play on that capex.
AMAT — HBM stack count growth raises wafer starts and process steps. NVDA's supply gap forces capacity adds across logic, HBM, packaging. Direct WFE read-through to the memory bottleneck.
LRCX — More layers and stacks equal more etch and deposition content. The 30pt gap pushes memory capex through 2027. Clean read-through.
KLAC — Process control wins because HBM package-level yield failures destroy entire high-value stacks. Defectivity becomes the cost driver as stack counts rise. Catches every wafer in a capacity-add cycle.
UCTT — Teen 2027E multiple on high-growth semicap subsystems. Positioning washout, not fundamentals, created the discount. Cheapest way to own the equipment upcycle. Risk: WFE stays range-bound until 2027 estimates move.
MKSI — Same setup as UCTT: deposition + metrology portfolio feeds NVDA's supply gap. Positioning suppressed the multiple. Re-rating starts when 2027 numbers move up.
AEIS — Power delivery and control for the semiconductor buildout. Teen 2027E multiple, direct advanced packaging / memory exposure. Cheaper beta to the same semicap cycle.
CLS — ODM with GPU + custom ASIC exposure at a teen 2027E multiple. Market left the group for dead while NVDA ramps. Cheapest beta to the ramp. Risk: margin dilution from hyperscaler concentration.
FLEX — GPU + custom ASIC ODM at a teen 2027E multiple. NVDA supply normalization expands TAM. Needs one strong margin guide to re-rate.
SANM — Lower-conviction but cheaper AI hardware beta than large-cap ODMs. Positioning washout likely overstates cycle risk. Too cheap for the embedded AI growth.
MOD — Data center industrial, large backlog, teen 2027E multiple. Direct expression of $1.3T 2027 hyperscaler capex. Higher long yields and tighter credit are the swing factor. Power/cooling, not GPUs, drive the story.
FTAI — BTM power and data center infrastructure, teen 2027E multiple. Credit market access is the key risk. Demand side secured by hyperscaler capex.
BW — Data center power / BTM generation backlog at a teen 2027E multiple. Direct beneficiary of the AI power bottleneck. Credit access is the swing factor.
GNRC — On-site gas generation for AI campuses expands TAM. Cheaper expression of the 2027 hyperscaler capex cycle. Rate and credit conditions remain the swing factor.
AVGO — Thor Ultra is an 800G AI NIC with 2.4B transistors and 97.9% of theoretical full-duplex bandwidth — keeps Broadcom competitive at the AI-NIC frontier. Custom silicon grows without wholesale NVDA displacement: NVDA content per GW rises from $18B to $40B, limiting the displacement math. Software ecosystem remains the open question.
MRVL — Custom ASIC beneficiary that doesn't need NVDA displacement. NVHBM adds a custom-HBM interface angle. Hyperscaler pipeline keeps growing into 2027.
QCOM — HBC roadmap commercializes 2027/2028, claims 6x bandwidth per watt vs HBM, targets phones, XR, cars, hyperscalers. Gen1 scale two years out, but the direction is real. MediaTek's 200G SerDes + Google TPU EMIB work just widened the competitive set — slow-burn share risk.
ARM — Grace CPU at $5B TTM revenue, ~$20B demand, doubling in FY28. CPU-per-GPU shifts from 1:4 to 1:1-2, accelerating Arm server socket adoption. But ARM screens rich — long-end rates are a direct multiple risk.
CIEN — Flagged among the richly-valued AI infra names. Networking content per GPU rises, but valuation already trades that. Less attractive r/r than the teen-multiple AI infra beta.
AMD — Vera Rubin delivers ~30x throughput per MW and 35x lower token cost vs Grace Blackwell Ultra. Win at chip level, still lose at system level — the bar just went up. Versal Premium Gen 2 / RF is defensive TAM, not an AI-GPU narrative changer.
AMZN — AWS deploys an incremental 2M NVIDIA GPUs FY2Q27-FY2Q29 on top of prior >1M plan — >3M gross additions, ~4-5GW of load, ~$100B to NVIDIA before CPUs, networking, NVLink. Largest disclosed single-customer volume commitment of the cycle. AWS is not wavering.
ORCL — Already running Vera Rubin racks per NVDA's production ramp. Early allocation is a competitive advantage in a supply-constrained market. Construction and power costs remain the offset.
MSFT — Among the first running Vera Rubin racks. Early access strengthens Azure's AI capacity position when OpenAI and enterprise workloads compete for scarce supply. Supports revenue trajectory without new cost detail.
HPQ — Record revenue but PC units declined — first major PC quarter showing memory inflation pass-through. ASPs up, units down, and HP says the pattern intensifies in H2. Squeezed between CSPs that swallow costs and consumers who walk. FY26 H2 margin guide is judgment day.
DELL — Same squeeze as HP. Higher BOM costs pressure client units and margins. AI servers offset some, not all. Next print needs a margin guide, not a revenue beat.
LNVGY — Samsung GAIA PIM AI-PC prototypes in Lenovo's hands — possible 2027 differentiator in a commoditized PC market. Memory inflation still squeezes the BOM and units.
AAPL — Sept 9 "Surprise and shine" kicks off the Ternus era, likely with a foldable; standard iPhone 18 pushes to 2027. Form-factor plus CEO transition in one quarter. Hinge/panel supply orders lead Q4 prints. M6 Pro/Max/Ultra packaging (SoIC-MH + WMCM) validates TSMC's advanced packaging roadmap.
WULF — Kentucky approved up to 482MW for Justified — key regulatory gate cleared for the ~$19B Anthropic lease. Delivery confidence improves for late-2027/early-2028. But WULF pays for 482MW for six years even if it uses less, and needs $4.0-4.5B of its own capital. Financing and construction remain the real gate.
P — Evercore raised FY27 to $5.03-5.07B revenue / $940-960M EBIT from $4.41-4.51B / $820-860M — well above Street growth of +21%. Pure Storage tracks ~37.5% growth with $5M+ deals +59%, $20M+ deals +385%. AI storage demand inflects into the model. Upgrades confirm storage as an AI read-through.
CSIQ — Beat revenue, missed EPS badly: -$1.40 vs -$0.11, GM only 13.9%. Battery storage grew 73% to 3.7GWh. Q3 guide missed. Storage growth real; the margin and guide are not.
DLTR — Revenue +7% to $4.9B, comp +3.7%, EPS beat at $2.70 including $1.31 of tariff refunds. FY26 guide above estimates but refund-driven. FCF $675M and $605M buybacks support. Quality of the beat is low.
SIMO — Investors trimmed memory-related positions after a massive re-rating. Price discovery done, waiting for operating income to catch up. Fundamentals up, marginal buyers exhausted. Pause in a cyclical up-move, not a trend break.
ASX — ASE benefits from secondary packaging, test, and substrate spillover as high-end packaging absorbs capacity. Less direct than TSMC, but utilization stays favorable. HBM and advanced packaging raise test content. Second-derivative AI long with lower visibility.
NBIS — First adopter of Groq 3 LPX rack-scale, runs Vera Rubin racks. Neocloud install base nearly triples from 3GW to 8GW by end-2026. Access to scarce compute plus a differentiated LPU offering. Neocloud economics remain contested as hyperscalers gain leverage.
CRWV — Among the first running Vera Rubin racks — lifeblood in a supply-constrained cycle. Low 2027E multiple, but financing access is the swing factor. NVDA's revenue-sharing and take-or-pay structures shift risk to the balance sheet.
SFTBY — NVDA's financial guarantee book includes ~$105B concentrated on SoftBank-related commitments. Portsmouth Campus starts at 4.25GW with ~1.5M GPUs per generation. Any SoftBank credit wobble becomes an NVDA balance-sheet event.
BABA — Qwen3.8-Flash trains at ~1/9th the cost of Qwen3.7-Plus with agent-economics pricing (RMB1/M input, RMB3/M output). Open-weight Flash-Next is early Qwen4 architecture. Deflationary force in frontier inference pricing. Chinese labs are exporting open-source cost pressure.
SSNLF — GAIA 4nm PIM prototypes in Lenovo/HP hands; LPDDR6-PIM spec nears JEDEC completion. PIM cuts workload time by over half. Also rides Qualcomm's HBC push. 2027 optionality, not near-term earnings. Flashlight Capital's tender offer is the first real governance activism under Korea's new law — holding discount could compress.
HXSCL — Highest-quality read-through to NVDA's memory bottleneck as a leading HBM supplier. Indiana $3.87B plant starts 2028, exactly when NVDA sees constraints easing. HBM contract prices up another 70-140% per TrendForce — mix skews to advanced HBM, incremental revenue high-margin. 2027 estimates look too low.
KIOXY — ¥1T ($6.3B) Iwate fab adds NAND capex from 2029. Near-term NAND pricing stays tight because capacity lands after the cycle. Supply-watch item for post-2028, not a current overhang.
SMSDY — SEMCO changes the pricing playbook: direct Q4 MLCC hikes to OEM/ODM — consumer X5R +25-30%, AI-server X6S +10-20%. Prior practice was agent-only adjustments. Structural shift in passive pricing power. Consumer hikes hit the demand-elastic end, so volume risk accompanies the pricing win.
MURAY — Key follow-on signal for MLCC inflation. If Murata matches SEMCO's Q4 hikes, passive inflation is broad, not one vendor. That adds another layer to terminal BOM pressure. No confirmation yet — watch Q4 quotes.
YAGOY — Potential follower in the MLCC hike cycle. If Yageo follows SEMCO's Q4 increases, terminal BOM pressure narrative gains another layer. Pricing cover from SEMCO makes a follow-on more likely.
MDTKF — MediaTek got 200G SerDes working and is the ASIC packaging partner for Google TPU at Intel EMIB. That makes it a credible datacenter competitor to Qualcomm. EMIB wins give MediaTek an advanced packaging pathway outside TSMC. Low-cost option on custom silicon.